Literature DB >> 21139144

European guideline for the management of hepatitis B and C virus infections, 2010.

G Brook1, V Soriano, C Bergin.   

Abstract

These are the guidelines on hepatitis B and C management for IUSTI/WHO in Europe, 2010. They describe the epidemiology, diagnosis, clinical features, treatment and prevention of hepatitis B and C with particular reference to sexual health clinical practice.

Entities:  

Mesh：

Year:  2010        PMID： 21139144     DOI： 10.1258/ijsa.2010.010234

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN： 0956-4624            Impact factor:   1.359


  11 in total

1.  A nested case-control study of maternal-neonatal transmission of hepatitis B virus in a Chinese population.

Authors:  Li-Zhang Chen; Wen-Qi Zhou; Shu-Shan Zhao; Zhi-Yu Liu; Shi-Wu Wen
Journal:  World J Gastroenterol       Date:  2011-08-21       Impact factor: 5.742

2.  3.0T ¹H magnetic resonance spectroscopy for assessment of steatosis in patients with chronic hepatitis C.

Authors:  Qian Zhang; Hui-Mao Zhang; Wen-Qian Qi; Yong-Gui Zhang; Ping Zhao; Jian Jiao; Jiang-Bin Wang; Chun-Yu Zhang
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

3.  3.0T 31P MR spectroscopy in assessment of response to antiviral therapy for chronic hepatitis C.

Authors:  Chun-Yu Zhang; Qian Zhang; Hui-Mao Zhang; Hai-Shan Yang
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

4.  Long-term effect on natural killer cells by interferon-α therapy on the outcomes of HCV infection.

Authors:  Xiaoli Hu; Yanfang Jiang; Xiurong Li; Yanhang Gao; Xiaoli Guo; Xiumei Chi; Hongqing Yan; Junyan Feng; Jin Zhong; Bing Sun; Xue Shao; Weihua Xiao; Yu Pan; Junqi Niu
Journal:  J Interferon Cytokine Res       Date:  2013-12-24       Impact factor: 2.607

5.  Identification of hepatitis B and C screening and patient management guidelines and availability of training for chronic viral hepatitis among health professionals in six European countries: results of a semi-quantitative survey.

Authors:  Angela Bechini; Abby Falla; Amena Ahmad; Irene Veldhuijzen; Sara Boccalini; Barbara Porchia; Miriam Levi
Journal:  BMC Infect Dis       Date:  2015-08-19       Impact factor: 3.090

6.  The Functional Difference of Dendritic Cells in HBeAg Negative Chronic Hepatitis B Patients with Three Different Spleen Deficiency Syndromes and the Therapeutic Evaluation of Chinese Medicine Intervention Based on Syndrome Differentiation.

Authors:  Lei Wang; Li Zhang; Xiaoxia Feng; Lianjun Xing; Wei Zhang; Kaiping Jiang; Haiyan Song; Guang Ji
Journal:  Evid Based Complement Alternat Med       Date:  2014-06-29       Impact factor: 2.629

7.  The acceptability and effectiveness of a questionnaire for the identification of risk factors for HIV and hepatitis B and C: An observational study in general practice.

Authors:  Amélie Aïm-Eusébi; Emmanuel Prothon; Catherine Majerholc; Diana Barger; Yazdan Yazdanpanah; Jean-Pierre Aubert
Journal:  Eur J Gen Pract       Date:  2017-11-27       Impact factor: 1.904

8.  Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic hepatitis B virus infected patients.

Authors:  Juan Lv; Qinglong Jin; Haibo Sun; Xiumei Chi; Xiaoli Hu; Hongqing Yan; Yu Pan; Weihua Xiao; Zhigang Tian; Jinlin Hou; Damo Xu; Zhengkun Tu; Junqi Niu
Journal:  Mediators Inflamm       Date:  2012-12-10       Impact factor: 4.711

9.  Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association.

Authors:  V D Hope; I Eramova; D Capurro; M C Donoghoe
Journal:  Epidemiol Infect       Date:  2013-05-29       Impact factor: 4.434

10.  Heads or Tails: Genotyping of Hepatitis C Virus Concerning the 2k/1b Circulating Recombinant Form.

Authors:  Wim Schuermans; Hans Orlent; Isabelle Desombere; Patrick Descheemaeker; Hans Van Vlierberghe; Anja Geerts; Xavier Verhelst; Marijke Reynders; Elizaveta Padalko
Journal:  Int J Mol Sci       Date:  2016-08-23       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.